• SENSEX
    NIFTY 50
Technology

Biologics, research services to be main drivers of growth in FY19, says Biocon

Updated : April 30, 2018 12:59 PM IST

The biologics and research services businesses of the company grew by 47% and 45%, respectively, in the fourth quarter of the fiscal year 2018.
The company has previously guided for USD 200 million in revenue from its biologics business and USD 250 million from research services business by FY19, and are on track to achieve those.
The Bengaluru-based firm had posted 2% increase in its consolidated net profit at Rs 130 crore for the fourth quarter ended March of 2017-18.
Biologics, research services to be main drivers of growth in FY19, says Biocon

You May Also Like

Live TV

recommended for you

Advertisement